GI
NVCR icon

GAMMA Investing’s NovoCure NVCR Stock Holding History

GAMMA Investing’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.6K Buy
918
+282
+44% +$4.71K ﹤0.01% 3132
2026
Q2 		$9.63K Buy
636
+50
+9% +$757 ﹤0.01% 3221
2026
Q1 		$6.39K Sell
586
-82
-12% -$1.02K ﹤0.01% 3272
2025
Q4 		$8.64K Buy
668
+508
+318% +$6.52K ﹤0.01% 3038
2025
Q3 		$2.07K Sell
160
-2,201
-93% -$29.4K ﹤0.01% 3443
2025
Q2 		$42K Sell
2,361
-443
-16% -$7.72K ﹤0.01% 2033
2025
Q1 		$50K Sell
2,804
-11
-0.4% -$250 ﹤0.01% 1792
2024
Q4 		$83.9K Sell
2,815
-25
-0.9% -$529 0.01% 1241
2024
Q3 		$44.4K Buy
2,840
+52
+2% +$943 ﹤0.01% 1572
2024
Q2 		$47.8K Sell
2,788
-92
-3% -$1.62K 0.01% 1226
2024
Q1 		$45K Buy
2,880
+2,118
+278% +$31.1K 0.01% 1113
2023
Q4 		$10.6K Buy
+762
New +$10.2K ﹤0.01% 1871

Other funds holding NVCR

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GA
GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return

GAMMA Investing's NVCR Position: Q3 2026 in Review

GAMMA Investing increased its NovoCure (NVCR) stake by 44% in Q3 2026, buying an estimated $4.71K and bringing the position to 918 shares worth $14.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3132.

GAMMA Investing first reported a position in NVCR in Q4 2023 and has held it in 12 quarters since. The position peaked at $83.9K in Q4 2024. 15 funds tracked by Wall St. Rank hold NVCR as of Q3 2026.

  • GAMMA Investing held 918 shares of NovoCure worth $14.6K as of Q3 2026.
  • GAMMA Investing bought 282 NovoCure shares in Q3 2026, an estimated $4.71K.
  • NovoCure made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3132 holding.
  • GAMMA Investing first reported a position in NovoCure in Q4 2023 and has held it in 12 quarters since.
  • GAMMA Investing's NovoCure position peaked at $83.9K in Q4 2024.
  • 15 funds tracked by Wall St. Rank held NovoCure as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.